Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 4 , Pages 368-374 , July 2010

Updated results of bladder-sparing trimodality approach for invasive bladder cancer

  • Almudena Zapatero, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Hospital Universitario de la Princesa, Madrid, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +349-15202315; fax: +349-15202315
    • ,
  • Carmen Martin de Vidales, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Hospital Universitario de la Princesa, Madrid, Spain
    • ,
  • Ramón Arellano, M.D.

      Affiliations

    • Department of Urology, Hospital Universitario de la Princesa, Madrid, Spain
    • ,
  • Gloria Bocardo, M.D.

      Affiliations

    • Department of Urology, Hospital Universitario de la Princesa, Madrid, Spain
    • ,
  • Mar Pérez, M.D.

      Affiliations

    • Department of Medical Oncology, Hospital Universitario de la Princesa, Madrid, Spain
    • ,
  • Patricia Ríos, M.D.

      Affiliations

    • Department of Radiation Oncology, Hospital Universitario de la Princesa, Madrid, Spain

Received 15 December 2008 ,Revised 21 January 2009 ,Accepted 22 January 2009.

References 

  1. Sweeney C, Bajorin DF, Sternberg C. Muscle-invasive bladder cancer: What have we learned and what's new on the horizon?. J Clin Oncol. 2008;8:200–208
  2. Rödel C, Weiss C, Sauer R. Organ preservation by combined modality treatment in bladder cancer: The European perspective. Semin Radiat Oncol. 2004;15:28–35
  3. Coen JJ, Zietman AL, Kaufman DS, et al. Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancer. Urol Oncol. 2007;25:76–84
  4. Fernando SA, Sandler HM. Multimodality bladder preservation therapy for muscle-invasive bladder tumors. Semin Oncol. 2007;34:129–134
  5. Chung PWM, Bristow RG, Milosevic MF, et al. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol. 2007;25:303–309
  6. Zapatero A, Martin de Vidales C, Marin A. Invasive bladder cancer: A single-institution experience with bladder-sparing approach. Int J Cancer Radiat Oncol Invest. 2000;90:287–294
  7. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radat Oncol Biol Phys. 1995;31:1341–1346
  8. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187–220
  9. Weiss C, Engehausen DG, Krause FS, et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys. 2007;68:1072–1080
  10. Zietman AL, Sacco D, Skowronski U, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol. 2003;170:1772–1776
  11. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol. 2002;20:3061–3071
  12. Hagan MP, Winter KA, Kaufman DS, et al. RTOG 97–06; initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57:665–672
  13. Milosevic M, Gospodarowicz M, Zietman A, et al. Radiotherapy for bladder cancer. Urology. 2007;69(Suppl 1A):80–92
  14. Ghersi D, Stewart LA, Parmar MKB, et al. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomized controlled trial. Lancet. 1999;354:533–540
  15. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. Lancet. 2003;361:1927–1934
  16. Nichols RC, Sweetser MG, Mahmood SK, et al. Radiation therapy and concomitant paclitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: A well-tolerated combination. Int J Cancer. 2000;90:281–286
  17. Sangar VK, McBain CA, Lyons J, et al. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys. 2005;61:420–425
  18. Dunst J, Weigel C, Heynemann H, et al. Preliminary results of simultaneous radiochemotherapy with paclitaxel for urinary bladder cancer. Strahlenther Onkol. 1999;175(Suppl. 3):7–10
  19. Majewski W, Maciejewski B, Majewski S, et al. Clinical radiobiology of stage T2–T3 bladder cancer. Int J Radiat Oncol Biol Phys. 2004;60:60–70
  20. Horwich A, Dearnaley D, Huddart R, et al. A randomized trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother Oncol. 2005;75:34–43
  21. Poortmans PM, Richaud P, Collette L, et al. EORTC Radiation Oncology Group Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder. Acta Oncol. 2008;47(5):937–940
  22. Cowan RA, McBain CA, Ryder WD, et al. Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:197–207
  23. Chakravarti A, Winter K, Wu CL, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2005;62:309–317
  24. Pollack A, Wu CS, Czerniak B, et al. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res. 1997;3:1823–1829

PII: S1078-1439(09)00029-5

doi: 10.1016/j.urolonc.2009.01.031

Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 4 , Pages 368-374 , July 2010

Article Tools

* Image Usage & Resolution